Shire Pharmaceuticals has presented new data demonstrating that Adderall XR (mixed salts of a single-entity amphetamine product) significantly improves symptoms in adults with attention-deficit/hyperactivity disorder (ADHD).
Nearly 75 percent of study participants experienced improvement in ADHD symptoms, according to preliminary results of the Quality of Life, Effectiveness, Safety, and Tolerability (Qu.E.S.T.) study. Qu.E.S.T. is a 30-week, open-label, multicenter investigation of adults, aged 18 and older, diagnosed with ADHD who receive treatment with once-daily Adderall XR.
This study was conducted in community practice settings at 74 U.S. and seven Canadian sites. The results from this interim analysis focus on data collected on 702 patients who completed a core 10-week phase.